Mahshid Mohammadian

Mahshid Mohammadian

Auto-generated profile, based on publicly available information

Mahshid Mohammadian

Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2020 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
NMNazila Fathi Maroufi
Nazila Fathi Maroufi
Vahid VahedianVahid Vahedian
Vahid Vahedian
MAMaryam Akbarzadeh
Maryam Akbarzadeh
MMMahshid Mohammadian
Mahshid Mohammadian
MZMohammadsaeid Zahedi
Mohammadsaeid Zahedi
TNTannaz Novinbahador
Tannaz Novinbahador

1 January 2017 in Research in Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
FKFatemeh Kheradmand
Fatemeh Kheradmand
MMMahshid Mohammadian
Mahshid Mohammadian
SZShima Zeynali
Shima Zeynali
AAAnahita Fathi Azarbayjani
Anahita Fathi Azarbayjani
MAMohammad Hassan Khadem Ansari
Mohammad Hassan Khadem Ansari
The use of heat shock protein 90 inhibitors like 17-allylamino-17-demethoxy-geldanamycin (17-AAG) has been recently introduced as an attractive anticancer therapy. It has been shown that 17-AAG may potentiate the inhibitory effects of some classical anticolorectal cancer (CRC) agents. In this study, two panels of colorectal carcinoma cell lines were used to evaluate the effects of 17-AAG in combination with capecitabine and oxaliplatin as double and triple combination therapies on the proliferation of CRC cell lines. HT-29 and all HCT-116 cell lines were seeded in culture media in the presence of different doses of the mentioned drugs in single, double, and triple combinations. Water-soluble tetrazolium-1 (WST-1) assay was used to investigate cell proliferation 24 h after treatments. Then, dose-response curves were plotted using WST-1outputs, and IC50 values were determined. For double and triple combinations respectively 0.5 × IC50 and 0.25 × IC50 were used. Data was analyzed with the software CompuSyn. Drug interactions were analyzed using Chou-Talalay method to calculate the combination index (CI).The data revealed that 17-AAG shows a potent synergistic interaction (CI < 1) with oxaliplatin and capecitabine in double combinations (0.5 × IC50) in both cell lines. In the case of triple combinations, the findings showed an antagonistic interaction (CI > 1) in HT-29 and a synergistic effect (CI < 1) in HCT-116 (0.25 × IC50) cell lines. It was concluded that double combinations of 17-AAG with oxaliplatin or capecitabine might be effective against HCT-116 and HT-29 cell lines. However, in triple combinations, positive results were seen only against HCT-116. Further investigation is suggested to confirm the effectiveness of these combinations in clinical trials.

1 March 2017
Verified
Journal Article
Open access
PDF file
NMNejad Mohamadi
Nejad Mohamadi
SKS Maryam Kazemi
S Maryam Kazemi
MMMahshid Mohammadian
Mahshid Mohammadian
AMAttabak Toofani Milani
Attabak Toofani Milani
YMYounes Moradi
Younes Moradi
AKAzim Akbarzadeh Khiyavi
Azim Akbarzadeh Khiyavi
Cancer is one of the most important issues in modern medicine and the most common cause of death after cardiovascular diseases in many countries. Brain cancer is one of the most common causes of cancer death among men and women, ranking third. Chemotherapeutic drugs that aim to prevent uncontrolled proliferation of cells in tissues of the body and induce apoptosis of tumor cells are prominent candidates for development. Since cisplatin has an apoptosis-inducing role, it is widely used as an anticancer agent. In this research, toxicity of cisplatin was studied with the C6 rat glioma cell lined using the MTT method. In addition, nanoparticles underwent SEM microscopic imaging. Particle average size, size distribution, polydispersity index (PDI) and zeta potential of poly butyl cyanoacrylate nanoparticles were found to be 222 nm, 0.470 ± 0.04 and 5.1 ± 0.2 mV, respectively. The results showed that nanoconjugates of cisplatin have more cytotoxic effects on C6 cells than the free drug (P<0.05), pointing to an enhanced potential of the synthesized nano-particles as a new nanocarrier for chemotherapy.

1 February 2019 in Gene
Verified
Journal Article
Closed access
SZShima Zeynali-Moghaddam
Shima Zeynali-Moghaddam
MMMahshid Mohammadian
Mahshid Mohammadian
FKFatemeh Kheradmand
Fatemeh Kheradmand
AAAnahita Fathi Azarbayjani
Anahita Fathi Azarbayjani
YRYousef Rasmi
Yousef Rasmi
HMHassan Malekinejad
Hassan Malekinejad

5 March 2019 in DARU Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
ZMZhino Moradi
Zhino Moradi
MMMahshid Mohammadian
Mahshid Mohammadian
HSHassan Saberi
Hassan Saberi
MEMeysam Ebrahimifar
Meysam Ebrahimifar
ZMZeinab Mohammadi
Zeinab Mohammadi
ZBZhaleh Behrouzkia
Zhaleh Behrouzkia

1 April 2019 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
ZAZhila Arshad
Zhila Arshad
SRSoheila Rezapour-Firouzi
Soheila Rezapour-Firouzi
MEMeysam Ebrahimifar
Meysam Ebrahimifar
AMAlireza Mosavi-Jarrahi
Alireza Mosavi-Jarrahi
MMMahshid Mohammadian
Mahshid Mohammadian
Background: The phosphatidylinositol 3-kinase/ protein kinase B /mammalian target of rapamycin (PI3K/Akt/mTOR) signaling regulates multiple cellular processes and organizes cell proliferation, survival, and differentiationwith the available nutrients, in particular, fatty acids. Polyunsaturated fatty acids (PUFAs) are cytotoxic to cancer cellsand play a critical role in the treatment of multiple sclerosis (MS) and diabetes mellitus (DM). PUFAs are produced inthe body by desaturases and elongases from dietary essential fatty acids (EFAs), primarily involving delta-6-desaturase(D6D). D6D is a rate-limiting enzyme for maintaining many aspects of lipid homeostasis and normal health. D6D isimportant to recognize the mechanisms that regulate the expression of this enzyme in humans. A lower level of D6D wasseen in breast tumors compared to normal tissues. Interestingly, the elevated serum level of D6D was seen in MS andDM, which explains the critical role of D6D in inflammatory diseases. Methods: We searched databases of PubMed,Web of Science (WOS), Google Scholar, Scopus and related studies by predefined eligibility criteria. We assessedtheir quality and extracted data. Results: Regarding the mTOR signaling pathway, there is remarkable contributions ofmany inflammatory diseases to attention to common metabolic pathways are depicted. Of course, we need to have theinsights into each disorder and their pathological process. The first step in balancing the intake of EFAs is to preventthe disruption of metabolism and expression of the D6D enzyme. Conclusions: The ω6 and ω3 pathways are two majorpathways in the biosynthesis of PUFAs. In both of these, D6D is a vital bifunctional enzyme desaturating linoleic acidor alpha-linolenic acid. Therefore, if ω6 and ω3 EFAs are given together in a ratio of 2: 1, the D6D expression will bedown-regulated and normalized.